Giuseppe Bronte Alberto Verlicchi Serena De Matteis Alice Rossi Alessandra Affatato Francesco Giulio Sullo Caterina Gianni Matteo Canale Marco Angelo Burgio Angelo Delmonte Michele Milella Lucio Crinò
10.3389/fimmu.2021.672219
Front Immunol
2021 May 27;12:672219.
ctla-4 lag-3 pd-1 t cell exhaustion immune checkpoint inhibitor myeloid-derived suppressor cells
CC BY
https://pubmed.ncbi.nlm.nih.gov/34122429/
Adenocarcinoma of Lung / drug therapy Antineoplastic Combined Chemotherapy Protocols / administration & dosage Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Myeloid-Derived Suppressor Cells / immunology
Adenocarcinoma of Lung / drug therapy Antineoplastic Combined Chemotherapy Protocols / administration & dosage Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Myeloid-Derived Suppressor Cells / immunology Case Reports Adenocarcinoma of Lung / immunology Aged Humans Ipilimumab / administration & dosage Lung Neoplasms / immunology Male Middle Aged Myeloid-Derived Suppressor Cells / drug effects Nivolumab / administration & dosage Tumor Escape / drug effects Tumor Escape / immunology Immune Checkpoint Inhibitors Ipilimumab Nivolumab
PMC8191501
34122429
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
2021